Morgan Stanley Reiterates Equal-Weight on BioNTech, Maintains $119 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $119.
July 24, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on BioNTech and maintained a price target of $119.
The news is directly about BioNTech and its rating by Morgan Stanley. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's view on the stock has not changed. This could have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100